In vitro skin permeation of monoolein nanoparticles containing hydroxypropyl beta-cyclodextrin/minoxidil complex.
Monoolein (MO) cubic phases entrapping hydroxypropyl beta-cyclodextrin (HPbetaCD)/minoxidil (MXD) complex were prepared by hydrating molten MO with the complex solution, where the concentrations of HPbetaCD/MXD were 1.0%/0.32%-19.4%/1.98%. Without HPbetaCD, the maximum content of MXD loaded in the cubic phase was only 0.071%, but with aid of HPbetaCD, the content in the cubic phase increased up to 5.72%. The nanoparticles of the cubic phase were prepared by a bath type sonication using a Pluronic F127 as a dispersant. HPbetaCD/MXD complex had little effect on the size and the structure of cubic phase nanoparticles. In vitro skin permeation of MXD loaded in the cubic phase nanoparticles (2.44 mg/cm(2) for 18 h), were higher than that of MXD dissolved in propylene glycol/water/ethanol (20/30/50, v/v/v) (1.91 mg/cm(2) for 18 h), but the amount of MXD remained within skin was higher with the MXD solution (0.068 mg/cm(2) for 18 h) than with the nanoparticles (0.023 mg/cm(2) for 18 h).
Kwon
Teak Kwan
TK
Division of Biotechnology & Bioengineering, Kangwon National University, Chunchon, Kangwon-do, Republic of Korea.
Kim
Jin Chul
JC
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000279:Administration, Cutaneous; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000737:chemistry* / Q000493:pharmacokinetics; D004339:Drug Compounding; D005260:Female; D005782:Gels; D005989:Glycerides / Q000737:chemistry* / Q000493:pharmacokinetics; D066298:In Vitro Techniques; D051379:Mice; D008812:Mice, Hairless; D046529:Microscopy, Electron, Transmission; D008914:Minoxidil / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D012869:Skin Absorption / Q000187:drug effects*; D012995:Solubility; D013499:Surface Properties; D047392:beta-Cyclodextrins / Q000737:chemistry* / Q000493:pharmacokinetics
D000959:Antihypertensive Agents; D004337:Drug Carriers; D005782:Gels; D005989:Glycerides; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D008914:Minoxidil; C005953:monoolein